Argen X SE EBIT

The latest EBIT for ARGX is $2.4B as of September 2026. That compares with $180M in the prior-year period — up 1291.0% year over year. That is below the Healthcare sector average of $99B. Investors often review this figure alongside Argen X SE's historical trend and sector peers before judging valuation or financial health.

Over the past year, ARGX's EBIT moved from $180M to $2.4B — a 1291.0% year-over-year increase. If the trend continues in the same direction for several quarters, it can signal a meaningful shift in Argen X SE's operating scale or balance-sheet position.

Against Healthcare companies, ARGX currently prints $2.4B for EBIT, while the sector average sits near $99B. That is roughly 97.5% below the sector mean. Large gaps often invite a closer look at Argen X SE's growth, margins, and balance sheet.

A EBIT figure of $2.4B for ARGX is a snapshot of scale on that line item. On its own it does not say whether the business is healthy — you also want growth rate, margins, and how the number compares with similar companies. The Healthcare average is about $99B. Explore the charts below for those layers of context.

After noting ARGX's EBIT ($2.4B), review year-over-year change from $180M, peer averages, and a few neighboring metrics such as revenue, margins, or valuation multiples. That combination usually beats staring at a single figure. The navigation links on this page jump you to those related views.